Abstract
Previous study has shown that F may prevent the renal side effects of I in infants with PDA. We, therefore, undertook a study to evaluate this effect in infants with PDA and oliguria in whom I therapy has been considered as contraindicated. Six infants (mean±S.D. B.W. 1.3±0.2 kg; G.A. 32±2 wks, Postn. A. 9.6±2.8 days) who had sign. PDA shunt, congestive heart failure, and oliguria due to pre-renal failure were given I, 0.3 mg/kg, followed immediately by F, 1 mg/kg, iv. Pre-renal failure was defined if U/0 was <1 ml/kg/hr and if FENa <2%. Cardiopulmonary status and renal functions were evaluated before and after one dose of I and F.
Sign, increases in U/O, FENa, FEcl, and GFR and sign, decreases in LA/AO, LVEDD were seen following I and F therapy. Four infants responded with ductus closure. Of the two whose ductus remained open, their U/O, and FENa also increased. This study indicates that F can prevent further renal dysfunctions expected from I therapy in infants who have PDA and are in pre-renal failure. A combination of I and F therapy can be safely used in these infants.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yeh, T., Wilks, A., Raval, D. et al. 425 FUROSEMIDE (F) PREVENTS THE RENAL SIDE EFFECTS OF INDOMETHACIN (I) IN PREMATURE INFANTS WITH PDA AND OLIGURIA. Pediatr Res 19, 181 (1985). https://doi.org/10.1203/00006450-198504000-00455
Issue Date:
DOI: https://doi.org/10.1203/00006450-198504000-00455